{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:42:30Z","timestamp":1780371750794,"version":"3.54.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>In autonomic failure, neurogenic orthostatic hypotension (nOH) and neurogenic supine hypertension (nSH) are interrelated conditions characterized by postural blood pressure (BP) dysregulation. nOH results in a sustained BP drop upon standing, which can lead to symptoms that include lightheadedness, orthostatic dizziness, presyncope, and syncope. nSH is characterized by elevated BP when supine and, although often asymptomatic, may increase long-term cardiovascular and cerebrovascular risk. This article reviews the pathophysiology and clinical characteristics of nOH and nSH, and describes the management of patients with both nOH and nSH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>Pressor medications required to treat the symptoms of nOH also increase the risk of nSH. Because nOH and nSH are hemodynamically opposed, therapies to treat one condition may exacerbate the other. The management of patients with nOH who also have nSH can be challenging and requires an individualized approach to balance the short- and long-term risks associated with these conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Approaches to manage neurogenic BP dysregulation include nonpharmacologic approaches and pharmacologic treatments. A stepwise treatment approach is presented to help guide neurologists in managing patients with both nOH and nSH.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11910-021-01104-3","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T13:00:34Z","timestamp":1615294834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension"],"prefix":"10.1007","volume":"21","author":[{"given":"Stuart H.","family":"Isaacson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Dashtipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Mehdirad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C.","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"issue":"8","key":"1104_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1097\/hjh.0000000000002078","volume":"37","author":"J Jordan","year":"2019","unstructured":"Jordan J, Fanciulli A, Tank J, Calandra-Buonaura G, Cheshire WP, Cortelli P, et al. Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. J Hypertens. 2019;37(8):1541\u20136. https:\/\/doi.org\/10.1097\/hjh.0000000000002078Scientific statement that summarizes the needs and challenges of managing and treating supine hypertension in patients who also have neurogenic orthostatic hypotension.","journal-title":"J Hypertens"},{"issue":"2","key":"1104_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","volume":"21","author":"R Freeman","year":"2011","unstructured":"Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69\u201372. https:\/\/doi.org\/10.1007\/s10286-011-0119-5.","journal-title":"Clin Auton Res."},{"issue":"11","key":"1104_CR3","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jacc.2018.05.079","volume":"72","author":"R Freeman","year":"2018","unstructured":"Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(11):1294\u2013309. https:\/\/doi.org\/10.1016\/j.jacc.2018.05.079.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"1104_CR4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccl.2012.09.003","volume":"31","author":"VC Nwazue","year":"2013","unstructured":"Nwazue VC, Raj SR. Confounders of vasovagal syncope: orthostatic hypotension. Cardiol Clin. 2013;31(1):89\u2013100.","journal-title":"Cardiol Clin."},{"issue":"5","key":"1104_CR5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10286-015-0307-9","volume":"25","author":"JE Celedonio","year":"2015","unstructured":"Celedonio JE, Arnold AC, Dupont WD, Ramirez CE, Diedrich A, Okamoto LE, et al. Residual sympathetic tone is associated with reduced insulin sensitivity in patients with autonomic failure. Clin Auton Res. 2015;25(5):309\u201315.","journal-title":"Clin Auton Res."},{"issue":"4","key":"1104_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10286-018-0529-8","volume":"28","author":"A Fanciulli","year":"2018","unstructured":"Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018;28(4):355\u201362. https:\/\/doi.org\/10.1007\/s10286-018-0529-8Consensus statement that defines neurogenic supine hypertension and delineates its severity in patients with autonomic failure.","journal-title":"Clin Auton Res."},{"issue":"1","key":"1104_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1161\/01.str.29.1.104","volume":"29","author":"V Novak","year":"1998","unstructured":"Novak V, Novak P, Spies JM, Low PA. Autoregulation of cerebral blood flow in orthostatic hypotension. Stroke. 1998;29(1):104\u201311. https:\/\/doi.org\/10.1161\/01.str.29.1.104.","journal-title":"Stroke."},{"issue":"5","key":"1104_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/mds.26079","volume":"30","author":"JA Palma","year":"2015","unstructured":"Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord. 2015;30(5):639\u201345. https:\/\/doi.org\/10.1002\/mds.26079.","journal-title":"Mov Disord."},{"issue":"1","key":"1104_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12883-018-1129-x","volume":"18","author":"DO Claassen","year":"2018","unstructured":"Claassen DO, Adler CH, Hewitt LA, Gibbons C. Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. BMC Neurol. 2018;18(1):125. https:\/\/doi.org\/10.1186\/s12883-018-1129-x.","journal-title":"BMC Neurol."},{"issue":"1","key":"1104_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/wnl.0000000000003452","volume":"88","author":"J Centi","year":"2017","unstructured":"Centi J, Freeman R, Gibbons CH, Neargarder S, Canova AO, Cronin-Golomb A. Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology. 2017;88(1):17\u201324. https:\/\/doi.org\/10.1212\/wnl.0000000000003452.","journal-title":"Neurology."},{"issue":"10","key":"1104_CR11","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1152\/japplphysiol.00266.2012","volume":"113","author":"JM Stewart","year":"2012","unstructured":"Stewart JM. Mechanisms of sympathetic regulation in orthostatic intolerance. J Appl Physiol (1985). 2012;113(10):1659\u201368. https:\/\/doi.org\/10.1152\/japplphysiol.00266.2012.","journal-title":"J Appl Physiol (1985)"},{"key":"1104_CR12","first-page":"473","volume":"28","author":"JA Palma","year":"2018","unstructured":"Palma JA, Redel-Traub G, Porciuncula A, Samaniego-Toro D, Lui YW, Norcliffe-Kaufmann L, et al. The impact of supine hypertension on target organ damage and mortality in patients with neurogenic orthostatic hypotension. Clin Auton Res. 2018;28:473.","journal-title":"Clin Auton Res."},{"key":"1104_CR13","doi-asserted-by":"publisher","unstructured":"Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet. 2000;355(9205):725\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(99)05320-9.","DOI":"10.1016\/S0140-6736(99)05320-9"},{"issue":"2","key":"1104_CR14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1524-6175.2001.00516.x","volume":"4","author":"J Jordan","year":"2002","unstructured":"Jordan J, Biaggioni I. Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension. J Clin Hypertens (Greenwich). 2002;4(2):139\u201345.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"1","key":"1104_CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/pr.115.012161","volume":"69","author":"I Biaggioni","year":"2017","unstructured":"Biaggioni I. The pharmacology of autonomic failure: from hypotension to hypertension. Pharmacol Rev. 2017;69(1):53\u201362.","journal-title":"Pharmacol Rev."},{"issue":"11","key":"1104_CR16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0024-3205(76)90210-1","volume":"18","author":"CR Lake","year":"1976","unstructured":"Lake CR, Ziegler MG, Kopin IJ. Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sci. 1976;18(11):1315\u201325.","journal-title":"Life Sci."},{"issue":"2","key":"1104_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/01.hyp.0000081216.11623.c3","volume":"42","author":"DS Goldstein","year":"2003","unstructured":"Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension. 2003;42(2):136\u201342. https:\/\/doi.org\/10.1161\/01.hyp.0000081216.11623.c3.","journal-title":"Hypertension."},{"issue":"11","key":"1104_CR18","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1185\/03007995.2015.1087988","volume":"31","author":"A Loavenbruck","year":"2015","unstructured":"Loavenbruck A, Sandroni P. Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions. Curr Med Res Opin. 2015;31(11):2095\u2013104. https:\/\/doi.org\/10.1185\/03007995.2015.1087988.","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"1104_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/CIRCULATIONAHA.108.805887","volume":"119","author":"DS Goldstein","year":"2009","unstructured":"Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139\u201346. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.805887.","journal-title":"Circulation."},{"issue":"12","key":"1104_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11910-015-0599-0","volume":"15","author":"KE McDonell","year":"2015","unstructured":"McDonell KE, Shibao CA, Claassen DO. Clinical relevance of orthostatic hypotension in neurodegenerative disease. Curr Neurol Neurosci Rep. 2015;15(12):78. https:\/\/doi.org\/10.1007\/s11910-015-0599-0.","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"3","key":"1104_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.27186","volume":"33","author":"EA Coon","year":"2018","unstructured":"Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 2018;33(3):349\u201358. https:\/\/doi.org\/10.1002\/mds.27186.","journal-title":"Mov Disord."},{"issue":"6","key":"1104_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMcp074189","volume":"358","author":"R Freeman","year":"2008","unstructured":"Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615\u201324. https:\/\/doi.org\/10.1056\/NEJMcp074189.","journal-title":"N Engl J Med."},{"issue":"4","key":"1104_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jamda.2013.10.014","volume":"15","author":"D Arbique","year":"2014","unstructured":"Arbique D, Cheek D, Welliver M, Vongpatanasin W. Management of neurogenic orthostatic hypotension. J Am Med Dir Assoc. 2014;15(4):234\u20139. https:\/\/doi.org\/10.1016\/j.jamda.2013.10.014.","journal-title":"J Am Med Dir Assoc."},{"issue":"23","key":"1104_CR24","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1161\/01.CIR.101.23.2710","volume":"101","author":"JR Shannon","year":"2000","unstructured":"Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, et al. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101(23):2710\u20135.","journal-title":"Circulation."},{"issue":"2","key":"1104_CR25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.115.06617","volume":"67","author":"AC Arnold","year":"2016","unstructured":"Arnold AC, Okamoto LE, Gamboa A, Black BK, Raj SR, Elijovich F, et al. Mineralocorticoid receptor activation contributes to the supine hypertension of autonomic failure. Hypertension. 2016;67(2):424\u20139.","journal-title":"Hypertension."},{"issue":"8","key":"1104_CR26","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00415-016-8375-x","volume":"264","author":"CH Gibbons","year":"2017","unstructured":"Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567\u201382. https:\/\/doi.org\/10.1007\/s00415-016-8375-x.","journal-title":"J Neurol"},{"issue":"5","key":"1104_CR27","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1161\/HYPERTENSIONAHA.109.136853","volume":"54","author":"EM Garland","year":"2009","unstructured":"Garland EM, Gamboa A, Okamoto L, Raj SR, Black BK, Davis TL, et al. Renal impairment of pure autonomic failure. Hypertension. 2009;54(5):1057\u201361. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.136853.","journal-title":"Hypertension."},{"issue":"966","key":"1104_CR28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/pgmj.2005.037457","volume":"82","author":"JE Naschitz","year":"2006","unstructured":"Naschitz JE, Slobodin G, Elias N, Rosner I. The patient with supine hypertension and orthostatic hypotension: a clinical dilemma. Postgrad Med J. 2006;82(966):246\u201353.","journal-title":"Postgrad Med J."},{"issue":"1-2","key":"1104_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2011.06.047","volume":"310","author":"Y Sharabi","year":"2011","unstructured":"Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci. 2011;310(1-2):123\u20138. https:\/\/doi.org\/10.1016\/j.jns.2011.06.047.","journal-title":"J Neurol Sci."},{"issue":"9718","key":"1104_CR30","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(10)60309-1","volume":"375","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375(9718):938\u201348.","journal-title":"Lancet."},{"key":"1104_CR31","doi-asserted-by":"publisher","unstructured":"Kaufmann H, Goldstein DS. Chapter 21\u2013Autonomic dysfunction in Parkinson disease. Handb Clin Neurol. 2013;117:259\u201378. https:\/\/doi.org\/10.1016\/B978-0-444-53491-0.00021-3.","DOI":"10.1016\/B978-0-444-53491-0.00021-3"},{"issue":"2","key":"1104_CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.24877","volume":"81","author":"H Kaufmann","year":"2017","unstructured":"Kaufmann H, Norcliffe-Kaufmann L, Palma JA, Biaggioni I, Low PA, Singer W, et al. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol. 2017;81(2):287\u201397.","journal-title":"Ann Neurol."},{"issue":"7","key":"1104_CR33","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1474-4422(15)00058-7","volume":"14","author":"PA Low","year":"2015","unstructured":"Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015;14(7):710\u20139.","journal-title":"Lancet Neurol."},{"issue":"9","key":"1104_CR34","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1007\/s00415-012-6736-7","volume":"260","author":"M Metzler","year":"2013","unstructured":"Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. 2013;260(9):2212\u20139. https:\/\/doi.org\/10.1007\/s00415-012-6736-7.","journal-title":"J Neurol."},{"issue":"5","key":"1104_CR35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.63.5.584","volume":"63","author":"JM Senard","year":"1997","unstructured":"Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"827","key":"1104_CR36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/pgmj.70.827.638","volume":"70","author":"GM Craig","year":"1994","unstructured":"Craig GM. Clinical presentation of orthostatic hypotension in the elderly. Postgrad Med J. 1994;70(827):638\u201342.","journal-title":"Postgrad Med J."},{"issue":"1","key":"1104_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10286-013-0219-5","volume":"24","author":"BH Shaw","year":"2014","unstructured":"Shaw BH, Claydon VE. The relationship between orthostatic hypotension and falling in older adults. Clin Auton Res. 2014;24(1):3\u201313.","journal-title":"Clin Auton Res."},{"issue":"3","key":"1104_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mdc3.12726","volume":"6","author":"C Fran\u00e7ois","year":"2019","unstructured":"Fran\u00e7ois C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, et al. Six-month use of droxidopa for neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2019;6(3):235\u201342. https:\/\/doi.org\/10.1002\/mdc3.12726.","journal-title":"Mov Disord Clin Pract."},{"issue":"5","key":"1104_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13696998.2017.1284668","volume":"20","author":"C Francois","year":"2017","unstructured":"Francois C, Biaggioni I, Shibao C, Ogbonnaya A, Shih HC, Farrelly E, et al. Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson\u2019s disease. J Med Econ. 2017;20(5):525\u201332. https:\/\/doi.org\/10.1080\/13696998.2017.1284668.","journal-title":"J Med Econ."},{"key":"1104_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.parkreldis.2017.11.344","volume":"47","author":"A Merola","year":"2017","unstructured":"Merola A, Sawyer RP, Artusi CA, Suri R, Berndt Z, Lopez-Castellanos JR, et al. Orthostatic hypotension in Parkinson disease: impact on health care utilization. Parkinsonism Relat Disord. 2017;47:45\u20139. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.11.344.","journal-title":"Parkinsonism Relat Disord."},{"issue":"18","key":"1104_CR41","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1212\/WNL.0000000000002086","volume":"85","author":"DS Goldstein","year":"2015","unstructured":"Goldstein DS, Holmes C, Sharabi Y, Wu T. Survival in synucleinopathies: a prospective cohort study. Neurology. 2015;85(18):1554\u201361.","journal-title":"Neurology."},{"issue":"2","key":"1104_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10286-015-0336-4","volume":"26","author":"A Fanciulli","year":"2016","unstructured":"Fanciulli A, Gobel G, Ndayisaba JP, Granata R, Duerr S, Strano S, et al. Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res. 2016;26(2):97\u2013105. https:\/\/doi.org\/10.1007\/s10286-015-0336-4.","journal-title":"Clin Auton Res."},{"issue":"1","key":"1104_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10286-015-0324-8","volume":"26","author":"T Umehara","year":"2016","unstructured":"Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res. 2016;26(1):15\u201321. https:\/\/doi.org\/10.1007\/s10286-015-0324-8.","journal-title":"Clin Auton Res."},{"issue":"5","key":"1104_CR44","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/01.HYP.30.5.1062","volume":"30","author":"J Shannon","year":"1997","unstructured":"Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. Hypertension. 1997;30(5):1062\u20137.","journal-title":"Hypertension."},{"issue":"6","key":"1104_CR45","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/HYPERTENSIONAHA.115.05913","volume":"66","author":"V Milazzo","year":"2015","unstructured":"Milazzo V, Maule S, Di Stefano C, Tosello F, Totaro S, Veglio F, et al. Cardiac organ damage and arterial stiffness in autonomic failure: comparison with essential hypertension. Hypertension. 2015;66(6):1168\u201375.","journal-title":"Hypertension."},{"issue":"10","key":"1104_CR46","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.amjhyper.2006.02.016","volume":"19","author":"S Maule","year":"2006","unstructured":"Maule S, Milan A, Grosso T, Veglio F. Left ventricular hypertrophy in patients with autonomic failure. Am J Hypertens. 2006;19(10):1049\u201354. https:\/\/doi.org\/10.1016\/j.amjhyper.2006.02.016.","journal-title":"Am J Hypertens."},{"issue":"7","key":"1104_CR47","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/jch.13023","volume":"19","author":"C Cuspidi","year":"2017","unstructured":"Cuspidi C, Sala C, Tadic M, Gherbesi E, De Giorgi A, Grassi G, et al. Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: an updated review. J Clin Hypertens (Greenwich). 2017;19(7):713\u201321. https:\/\/doi.org\/10.1111\/jch.13023.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"10","key":"1104_CR48","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/00004872-199816100-00006","volume":"16","author":"M Plaschke","year":"1998","unstructured":"Plaschke M, Trenkwalder P, Dahlheim H, Lechner C, Trenkwalder C. Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson's disease and multiple system atrophy. J Hypertens. 1998;16(10):1433\u201341.","journal-title":"J Hypertens."},{"issue":"2","key":"1104_CR49","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/HYPERTENSIONAHA.108.124552","volume":"53","author":"LE Okamoto","year":"2009","unstructured":"Okamoto LE, Gamboa A, Shibao C, Black BK, Diedrich A, Raj SR, et al. Nocturnal blood pressure dipping in the hypertension of autonomic failure. Hypertension. 2009;53(2):363\u20139.","journal-title":"Hypertension."},{"issue":"10","key":"1104_CR50","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jash.2016.07.009","volume":"10","author":"H Kaufmann","year":"2016","unstructured":"Kaufmann H, Norcliffe-Kaufmann L, Hewitt LA, Rowse GJ, White WB. Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. J Am Soc Hypertens. 2016;10(10):819\u201326. https:\/\/doi.org\/10.1016\/j.jash.2016.07.009.","journal-title":"J Am Soc Hypertens."},{"key":"1104_CR51","doi-asserted-by":"publisher","unstructured":"Di Stefano C, Sobrero G, Milazzo V, Vallelonga F, Romagnolo A, Zibetti M, et al. Cardiac organ damage in patients with Parkinson's disease and reverse dipping. J Hypertens. 2019. https:\/\/doi.org\/10.1097\/hjh.0000000000002249. A study that showed patients with Parkinson disease who also had nocturnal hypertension\/reverse dipping had higher left ventricular mass and increased prevalence of left ventricle hypertrophy than nonreverse patients with Parkinson disease; the magnitude of the increase in left ventricular in reverse-dipping patients was similar to that measured in patients with essential hypertension.","DOI":"10.1097\/hjh.0000000000002249"},{"issue":"6","key":"1104_CR52","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.282.6.539","volume":"282","author":"JA Staessen","year":"1999","unstructured":"Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282(6):539\u201346.","journal-title":"JAMA."},{"key":"1104_CR53","doi-asserted-by":"crossref","unstructured":"Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama Study. J Hypertens. 2002;20(11):2183\u20139.","DOI":"10.1097\/00004872-200211000-00017"},{"issue":"6","key":"1104_CR54","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1161\/HYPERTENSIONAHA.107.087262","volume":"49","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension. 2007;49(6):1235\u201341.","journal-title":"Hypertension."},{"issue":"8","key":"1104_CR55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1751-7176.2011.00480.x","volume":"13","author":"CT Coleman","year":"2011","unstructured":"Coleman CT, Stowasser M, Jenkins C, Marwick TH, Sharman JE. Central hemodynamics and cardiovascular risk in nondippers. J Clin Hypertens (Greenwich). 2011;13(8):557\u201362.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"2","key":"1104_CR56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0828-282X(07)70733-X","volume":"23","author":"FS Routledge","year":"2007","unstructured":"Routledge FS, McFetridge-Durdle JA, Dean CR. Night-time blood pressure patterns and target organ damage: a review. Can J Cardiol. 2007;23(2):132\u20138.","journal-title":"Can J Cardiol."},{"key":"1104_CR57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/IBPC.S4364","volume":"2","author":"O Friedman","year":"2009","unstructured":"Friedman O, Logan AG. Can nocturnal hypertension predict cardiovascular risk? Integr Blood Press Control. 2009;2:25\u201337.","journal-title":"Integr Blood Press Control."},{"key":"1104_CR58","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/VHRM.S53983","volume":"10","author":"SH Isaacson","year":"2014","unstructured":"Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014;10:169\u201376. https:\/\/doi.org\/10.2147\/VHRM.S53983.","journal-title":"Vasc Health Risk Manag."},{"issue":"3","key":"1104_CR59","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.pharmthera.2011.05.009","volume":"134","author":"C Shibao","year":"2012","unstructured":"Shibao C, Okamoto L, Biaggioni I. Pharmacotherapy of autonomic failure. Pharmacol Ther. 2012;134(3):279\u201386. https:\/\/doi.org\/10.1016\/j.pharmthera.2011.05.009.","journal-title":"Pharmacol Ther."},{"key":"1104_CR60","unstructured":"Northera\u00ae (droxidopa). Full Prescribing Information, Lundbeck NA Ltd, Deerfield, IL, 2017."},{"issue":"1","key":"1104_CR61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12883-017-0867-5","volume":"17","author":"I Biaggioni","year":"2017","unstructured":"Biaggioni I, Hewitt LA, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol. 2017;17(1):90. https:\/\/doi.org\/10.1186\/s12883-017-0867-5.","journal-title":"BMC Neurol."},{"key":"1104_CR62","unstructured":"ProAmatine\u00ae (midodrine hydrochloride). Full Prescribing Information, Shire US Inc., Lexington, MA, 2017."},{"issue":"13","key":"1104_CR63","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","volume":"277","author":"PA Low","year":"1997","unstructured":"Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046\u201351.","journal-title":"JAMA."},{"issue":"1","key":"1104_CR64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0002-9343(93)90230-M","volume":"95","author":"J Jankovic","year":"1993","unstructured":"Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38\u201348.","journal-title":"Am J Med."},{"issue":"1","key":"1104_CR65","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1212\/WNL.51.1.120","volume":"51","author":"RA Wright","year":"1998","unstructured":"Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120\u20134.","journal-title":"Neurology."},{"issue":"3","key":"1104_CR66","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1208\/s12248-016-0041-9","volume":"19","author":"N Hamitouche","year":"2017","unstructured":"Hamitouche N, Comets E, Ribot M, Alvarez JC, Bellissant E, Laviolle B. Population pharmacokinetic-pharmacodynamic model of oral fludrocortisone and intravenous hydrocortisone in healthy volunteers. AAPS J. 2017;19(3):727\u201335. https:\/\/doi.org\/10.1208\/s12248-016-0041-9.","journal-title":"AAPS J."},{"issue":"4","key":"1104_CR67","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/ene.13260","volume":"24","author":"SR Schreglmann","year":"2017","unstructured":"Schreglmann SR, Buchele F, Sommerauer M, Epprecht L, Kagi G, Hagele-Link S, et al. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. Eur J Neurol. 2017;24(4):545\u201351. https:\/\/doi.org\/10.1111\/ene.13260.","journal-title":"Eur J Neurol."},{"issue":"7","key":"1104_CR68","first-page":"367","volume":"36","author":"T Hakamaki","year":"1998","unstructured":"Hakamaki T, Rajala T, Lehtonen A. Ambulatory 24-h blood pressure recordings in patients with Parkinson's disease with or without fludrocortisone. Int J Clin Pharmacol Ther. 1998;36(7):367\u20139.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"6","key":"1104_CR69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/hrt.76.6.507","volume":"76","author":"RM Hussain","year":"1996","unstructured":"Hussain RM, McIntosh SJ, Lawson J, Kenny RA. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart. 1996;76(6):507\u20139.","journal-title":"Heart."},{"issue":"3-4","key":"1104_CR70","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1527-3466.2006.00189.x","volume":"24","author":"DS Goldstein","year":"2006","unstructured":"Goldstein DS. L-dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006;24(3-4):189\u2013203. https:\/\/doi.org\/10.1111\/j.1527-3466.2006.00189.x.","journal-title":"Cardiovasc Drug Rev."},{"key":"1104_CR71","unstructured":"Drugs.com. Fludrocortisone FDA Professional Drug Information. https:\/\/www.drugs.com\/pro\/fludrocortisone.html. Accessed February 11 2020."},{"issue":"6","key":"1104_CR72","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/01.CIR.0000083721.49847.D7","volume":"108","author":"H Kaufmann","year":"2003","unstructured":"Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724\u20138. https:\/\/doi.org\/10.1161\/01.CIR.0000083721.49847.D7.","journal-title":"Circulation."},{"key":"1104_CR73","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fphys.2014.00270","volume":"5","author":"AC Arnold","year":"2014","unstructured":"Arnold AC, Ramirez CE, Choi L, Okamoto LE, Gamboa A, Diedrich A, et al. Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure. Front Physiol. 2014;5:270. https:\/\/doi.org\/10.3389\/fphys.2014.00270.","journal-title":"Front Physiol."},{"issue":"2","key":"1104_CR74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0002-9343(98)00193-4","volume":"105","author":"J Jordan","year":"1998","unstructured":"Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med. 1998;105(2):116\u201324.","journal-title":"Am J Med."},{"issue":"11","key":"1104_CR75","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1007\/s11606-013-2520-3","volume":"28","author":"AK Parsaik","year":"2013","unstructured":"Parsaik AK, Singh B, Altayar O, Mascarenhas SS, Singh SK, Erwin PJ, et al. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013;28(11):1496\u2013503. https:\/\/doi.org\/10.1007\/s11606-013-2520-3.","journal-title":"J Gen Intern Med."},{"key":"1104_CR76","doi-asserted-by":"publisher","unstructured":"Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K. Standing and supine blood pressure outcomes associated with droxidopa and midodrine in patients with neurogenic orthostatic hypotension: a Bayesian meta-analysis and mixed treatment comparison of randomized trials. Ann Pharmacother. 2018;52(12):1182\u201394. https:\/\/doi.org\/10.1177\/1060028018786954A mixed-treatment meta-analysis showing that compared with placebo, the relative risk of supine hypertension was significantly higher for midodrine but not for droxidopa.","DOI":"10.1177\/1060028018786954"},{"issue":"6","key":"1104_CR77","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0002-9343(99)80246-0","volume":"99","author":"FM Fouad-Tarazi","year":"1995","unstructured":"Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99(6):604\u201310.","journal-title":"Am J Med."},{"key":"1104_CR78","unstructured":"Mestinon\u00ae (pyridostigmine bromide). Full Prescribing Information, ICN Pharmaceuticals, Costa Mesa, CA, 2001."},{"issue":"5","key":"1104_CR79","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/bf00636797","volume":"18","author":"SM Aquilonius","year":"1980","unstructured":"Aquilonius SM, Eckern\u00e4s SA, Hartvig P, Lindstr\u00f6m B, Osterman PO. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol. 1980;18(5):423\u20138. https:\/\/doi.org\/10.1007\/bf00636797.","journal-title":"Eur J Clin Pharmacol."},{"issue":"9","key":"1104_CR80","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/jnnp.74.9.1294","volume":"74","author":"W Singer","year":"2003","unstructured":"Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74(9):1294\u20138.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"1104_CR81","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1161\/HYPERTENSIONAHA.110.154898","volume":"56","author":"C Shibao","year":"2010","unstructured":"Shibao C, Okamoto LE, Gamboa A, Yu C, Diedrich A, Raj SR, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56(5):847\u201351. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.154898.","journal-title":"Hypertension."},{"issue":"4","key":"1104_CR82","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/archneur.63.4.noc50340","volume":"63","author":"W Singer","year":"2006","unstructured":"Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63(4):513\u20138. https:\/\/doi.org\/10.1001\/archneur.63.4.noc50340.","journal-title":"Arch Neurol."},{"issue":"10","key":"1104_CR83","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1212\/wnl.0000000000004340","volume":"89","author":"JI Byun","year":"2017","unstructured":"Byun JI, Moon J, Kim DY, Shin H, Sunwoo JS, Lim JA, et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. Neurology. 2017;89(10):1078\u201386. https:\/\/doi.org\/10.1212\/wnl.0000000000004340.","journal-title":"Neurology."},{"issue":"2","key":"1104_CR84","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.autneu.2013.08.064","volume":"177","author":"C Shibao","year":"2013","unstructured":"Shibao C, Grijalva CG, Lipsitz LA, Biaggioni I, Griffin MR. Early discontinuation of treatment in patients with orthostatic hypotension. Auton Neurosci. 2013;177(2):291\u20136. https:\/\/doi.org\/10.1016\/j.autneu.2013.08.064.","journal-title":"Auton Neurosci."},{"issue":"6014","key":"1104_CR85","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/bmj.1.6014.872","volume":"1","author":"IW Campbell","year":"1976","unstructured":"Campbell IW, Ewing DJ, Clarke BF. Therapeutic experience with fludrocortisone in diabetic postural hypotension. Br Med J. 1976;1(6014):872\u20134.","journal-title":"Br Med J."},{"issue":"1","key":"1104_CR86","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archneur.1975.00490430072013","volume":"32","author":"MM Hoehn","year":"1975","unstructured":"Hoehn MM. Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch Neurol. 1975;32(1):50\u20131.","journal-title":"Arch Neurol."},{"key":"1104_CR87","doi-asserted-by":"publisher","unstructured":"Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298\u2013308. https:\/\/doi.org\/10.1002\/mdc3.12478A review article describing the diagnosis and management of neurogenic orthostatic hypotension and providing a summary of key nonpharmacologic and pharmacologic approaches for the treatment of patients with neurogenic orthostatic hypotension.","DOI":"10.1002\/mdc3.12478"},{"key":"1104_CR88","doi-asserted-by":"crossref","unstructured":"Kaufmann H, Biaggioni I. Chapter 63 - Disorders of the autonomic nervous system. In: Fillit HM, Rockwood K, Woodhouse K, editors. Brocklehurst's Textbook of Geriatric Medicine and Gerontology. 7th ed. Philadelphia: W.B. Saunders; 2010. p. 498\u2013510.","DOI":"10.1016\/B978-1-4160-6231-8.10063-7"},{"issue":"6 Pt 1","key":"1104_CR89","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1161\/01.hyp.19.6.567","volume":"19","author":"M Pirpiris","year":"1992","unstructured":"Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension. 1992;19(6 Pt 1):567\u201374. https:\/\/doi.org\/10.1161\/01.hyp.19.6.567.","journal-title":"Hypertension."},{"issue":"suppl 1","key":"1104_CR90","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10286-007-1003-1","volume":"18","author":"R Freeman","year":"2008","unstructured":"Freeman R. Current pharmacologic treatment for orthostatic hypotension. Clin Auton Res. 2008;18(suppl 1):14\u20138. https:\/\/doi.org\/10.1007\/s10286-007-1003-1.","journal-title":"Clin Auton Res."},{"issue":"10","key":"1104_CR91","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1524-6175.2005.04139.x","volume":"7","author":"J Handler","year":"2005","unstructured":"Handler J. Symptomatic orthostatic hypotension\/supine hypertension. J Clin Hypertens (Greenwich). 2005;7(10):612\u20136. https:\/\/doi.org\/10.1111\/j.1524-6175.2005.04139.x.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"5","key":"1104_CR92","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/mds.26086","volume":"30","author":"RA Hauser","year":"2015","unstructured":"Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord. 2015;30(5):646\u201354.","journal-title":"Mov Disord."},{"issue":"4","key":"1104_CR93","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1212\/WNL.0000000000000615","volume":"83","author":"H Kaufmann","year":"2014","unstructured":"Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328\u201335. https:\/\/doi.org\/10.1212\/WNL.0000000000000615.","journal-title":"Neurology."},{"key":"1104_CR94","doi-asserted-by":"crossref","unstructured":"Grijalva CG, Biaggioni I, Griffin MR, Shibao CA. Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. J Am Heart Assoc. 2017;6(10):e006848 A retrospective cohort study of patients with orthostatic hypotension showing that patients treated with fludrocortisone had a 20% greater risk of all-cause hospitalization compared with patients treated with midodrine and that those patients who also had congestive heart failure had even a greater risk (42%).","DOI":"10.1161\/JAHA.117.006848"},{"issue":"5","key":"1104_CR95","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10072-012-1251-2","volume":"34","author":"A Mazza","year":"2013","unstructured":"Mazza A, Ravenni R, Antonini A, Casiglia E, Rubello D, Pauletto P. Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features. Neurol Sci. 2013;34(5):621\u20137. https:\/\/doi.org\/10.1007\/s10072-012-1251-2.","journal-title":"Neurol Sci."},{"issue":"2","key":"1104_CR96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2796.1992.tb00563.x","volume":"232","author":"AD Ten Harkel","year":"1992","unstructured":"Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med. 1992;232(2):139\u201345.","journal-title":"J Intern Med."},{"issue":"4","key":"1104_CR97","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1172\/JCI118871","volume":"98","author":"G Zeng","year":"1996","unstructured":"Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996;98(4):894\u20138.","journal-title":"J Clin Invest."},{"issue":"8","key":"1104_CR98","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1586\/14779072.2015.1057504","volume":"13","author":"H Kaufmann","year":"2015","unstructured":"Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther. 2015;13(8):875\u201391. https:\/\/doi.org\/10.1586\/14779072.2015.1057504.","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"1104_CR99","volume-title":"Full Prescribing Information","author":"Cozaar (losartan potassium)","year":"2018","unstructured":"Cozaar (losartan potassium). Full Prescribing Information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; 2018."},{"key":"1104_CR100","volume-title":"Full Prescribing Information","author":"Nitro-Dur (nitroglycerin patch)","year":"2014","unstructured":"Nitro-Dur (nitroglycerin patch). Full Prescribing Information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; 2014."},{"key":"1104_CR101","volume-title":"Full Prescribing Information","author":"Capoten (captopril)","year":"2012","unstructured":"Capoten (captopril). Full Prescribing Information. Spring Valley, NY: Par Pharmaceutical Companies, Inc.; 2012."},{"key":"1104_CR102","unstructured":"Apresoline (hydralazine). Full prescribing information, Ciba-Geigy Corporation, Summit, NJ, 1995."},{"issue":"3","key":"1104_CR103","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1161\/HYPERTENSIONAHA.111.00377","volume":"61","author":"AC Arnold","year":"2013","unstructured":"Arnold AC, Okamoto LE, Gamboa A, Shibao C, Raj SR, Robertson D, et al. Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. Hypertension. 2013;61(3):701\u20136. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.00377.","journal-title":"Hypertension."},{"issue":"1","key":"1104_CR104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1681\/ASN.V10135","volume":"10","author":"J Jordan","year":"1999","unstructured":"Jordan J, Shannon JR, Pohar B, Paranjape SY, Robertson D, Robertson RM, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol. 1999;10(1):35\u201342.","journal-title":"J Am Soc Nephrol."},{"key":"1104_CR105","unstructured":"Procardia\u00ae (nifedipine capsule). Full prescribing information. New York, NY: Pfizer Inc; 2016."},{"key":"1104_CR106","unstructured":"Inspra (eplerenone). Full Prescribing Information, Pfizer, New York, NY, USA, 2008."},{"issue":"8","key":"1104_CR107","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40263-017-0453-9","volume":"31","author":"J Baker","year":"2017","unstructured":"Baker J, Kimpinski K. Management of supine hypertension complicating neurogenic orthostatic hypotension. CNS Drugs. 2017;31(8):653\u201363.","journal-title":"CNS Drugs."},{"issue":"5","key":"1104_CR108","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/mds.20755","volume":"21","author":"TM Young","year":"2006","unstructured":"Young TM, Asahina M, Watson L, Mathias CJ. Hemodynamic effects of clonidine in two contrasting models of autonomic failure: multiple system atrophy and pure autonomic failure. Mov Disord. 2006;21(5):609\u201315. https:\/\/doi.org\/10.1002\/mds.20755.","journal-title":"Mov Disord."},{"issue":"1","key":"1104_CR109","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1161\/HYPERTENSIONAHA.107.089961","volume":"50","author":"C Shibao","year":"2007","unstructured":"Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50(1):47\u201353. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.089961.","journal-title":"Hypertension."},{"issue":"16","key":"1104_CR110","doi-asserted-by":"crossref","first-page":"e1539","DOI":"10.1212\/WNL.0000000000006369","volume":"91","author":"JA Palma","year":"2018","unstructured":"Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology. 2018;91(16):e1539\u2013e44.","journal-title":"Neurology."}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-021-01104-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-021-01104-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-021-01104-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T16:05:37Z","timestamp":1619625937000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-021-01104-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1007\/s11910-021-01104-3","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"21 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"SH Isaacson has served as a consultant and received honoraria for CME, research grants, and\/or promotional speaker on behalf of AbbVie, Acadia, Acorda, Adamas, Addex, Affiris, Alexva, Allergan, Amarantus, Amneal, Axovant, Benevolent, Biogen, Britannia, Cadent, Cala, Cerecor, Cipla, Eli Lilly, Enterin, GE Healthcare, Global Kinetics, Impax, Impel, Intec Pharma, Ipsen, Jazz, Kyowa, Lundbeck, Merz, Michael J. Fox Foundation, Mitsubishi Tanabe, Neuralym, Neurocrine, Neuroderm, Parkinson Study Group, Pharma2B, Prilenia, Promentis, Revance, Roche, Sanofi, Sunovion, Sun Pharma, Teva, Theravance, UCB, US World Meds, and Zambon. K Dashtipour has served as an advisor, consultant, or speaker for AbbVie, Acadia, Acorda, Adamas, Allergan, Amneal, Ipsen, Kyowa Kirin, Lundbeck, Neurocrine, Revance, Sunovion, Teva, and US WorldMeds. AA Mehdirad has served as a speaker for Lundbeck, Pfizer, and Bristol-Myers Squibb. AC Peltier has received fees for consultancy, honoraria, and\/or travel\/lodging from Lundbeck, Alnylam and Akcea, CSL Behring, and Daiichi Sankyo Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"18"}}